Peptide Mythbuster · Myth #005
BIG PHARMA DOESN'T SELL PEPTIDES
The billion-dollar blind spot in this argument
Verdict: BUSTED
01 / The claim
What people say
If peptides actually worked, pharmaceutical companies would be selling them — the fact that they don't proves peptides are just snake oil.Skeptic talking point
02 / Evidence
The data
Each point of evidence assessed against the original claim.
Refutes
Ozempic Revenue
Novo Nordisk's semaglutide products generated $21 billion in 2023. It's a 31-amino-acid peptide.
Refutes
Mounjaro Sales
Eli Lilly's tirzepatide hit $5.2 billion in its first full year. Also a peptide.
Refutes
FDA Approvals
Over 80 peptide drugs have received FDA approval. Dozens more in clinical trials.
Neutral
Patent Strategy
Pharma companies aggressively patent peptide modifications to maintain market exclusivity.
Neutral
Compounding Threat
Shortage declarations allowed compounders to produce semaglutide — pharma lobbied to end this.
Refutes
Price Differential
Branded Ozempic costs $900-1000/month. Compounded semaglutide ran $150-300 during shortages.
Refutes
Market Growth
Global peptide therapeutics market projected to exceed $90 billion by 2030.
03 / Verdict
The ruling
BUSTED
Pharmaceutical companies generate tens of billions annually from peptide drugs. The argument collapses under the weight of Ozempic alone.
04 / Key facts
The science
- 01$50+ BILLION ANNUALLYCombined GLP-1 peptide drug revenue in 2023. Pharma doesn't ignore molecules that print money.
- 0280+ APPROVEDFDA-approved peptide drugs currently on market, treating diabetes, cancer, osteoporosis, and more.
- 03INSULIN IS A PEPTIDEThe most prescribed drug in diabetes history is a 51-amino-acid peptide. Discovered 1921. Still selling.
- 04COMPOUNDING WARSPharma's fight isn't against peptides — it's against anyone else making them affordably.
05 / Deep dive
Why it matters
Peptide therapeutics represent one of pharma's fastest-growing sectors. GLP-1 agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are peptide drugs generating over $50 billion in combined annual revenue. The real tension isn't whether peptides work — it's whether compounding pharmacies can offer similar molecules outside the patent-protected pricing structure.
06 / Sources
References
- Trends in peptide drug discoveryMuttenthaler M, King GF, Adams DJ, Alewood PF (2021). Nature Reviews Drug Discovery. View source
- GLP-1 physiology informs the pharmacotherapy of obesityDrucker DJ (2022). Molecular Metabolism. View source
- Annual Report 2023Novo Nordisk (2024). Novo Nordisk Corporate Filing. View source
- Therapeutic peptides: current applications and future directionsWang L, et al. (2022). Signal Transduction and Targeted Therapy. View source
- GLP-1
- pharma
- economics
- compounding
- semaglutide